Predict your next investment

Venture Capital
searscapital.net

See what CB Insights has to offer

Investments

27

Portfolio Exits

5

Funds

1

About Sears Capital Management

Sears Capital Management, Inc. is a venture investment and portfolio management firm specializing in the life sciences. Since its founding in 1994, Sears Capital Management and its affiliated funds have provided seed capital and early stage financing for life science companies and startups.Sears Capital Management's investment areas are pharmaceuticals and medical devices. In addition, Sears Capital Management manages a portfolio of publicly traded life science company stocks.

Sears Capital Management Headquarter Location

300 3rd Street

Los Altos, California, 94022-3628,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Sears Capital Management News

Amgen Partners with SiteOne to Develop Pain Treatments

Jan 6, 2017

Amgen will collaborate with SiteOne Therapeutics to develop the Montana-based biotech’s portfolio of novel sodium ion channel 1.7 (NaV1.7) inhibitors for acute and chronic pain, SiteOne said today. While the value of the collaboration was not disclosed, SiteOne did say it formally closed on a $15 million Series B financing round led by Amgen, with participation from founding investors Next Frontier Capital, 2M Companies, Mission Bay Capital, Sears Capital Management, Biobrit, and Z Investments. “This Series B financing and collaboration with Amgen will allow us to accelerate the development of our NaV1.7 therapeutic candidates in multiple potential applications for managing acute and chronic pain without the addiction potential and other significant side-effects of existing therapies,” Stan Abel, SiteOne’s president and CEO, said in a statement. “The opioid crisis in the U.S. has created a critical need for safe and effective nonopioid solutions for managing pain,” Abel added. The company focuses on advancing treatments for moderate to severe pain that target the voltage-gated NaV1.7 channel. According to SiteOne, development of drugs targeting NaV1.7 has been challenging due to the difficulty of achieving selectivity for NaV1.7 over other closely related sodium ion channel isoforms. SiteOne says it has overcome that challenge through its discovery engine, which leverages natural sodium channel inhibitors of marine origin. “NaV1.7 is a target of great interest for neuropathic pain due to its human genetic validation," stated David Reese, svp of translational sciences at Amgen. SiteOne is headquartered in Bozeman, MT, with a research team based at QB3 in San Francisco. The company was founded to commercialize technology licensed from Stanford University and has won more than $3 million in NIH Small Business Innovation Research (SBIR) grant funding in addition to support from its founding investors. To enjoy more articles like this from GEN, click here to subscribe now! ×

Sears Capital Management Investments

27 Investments

Sears Capital Management has made 27 investments. Their latest investment was in SiteOne Inc. as part of their Series B on January 1, 2017.

CBI Logo

Sears Capital Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/6/2017

Series B

SiteOne Inc.

$15M

No

1

1/6/2017

Series B

SiteOne Therapeutics

$15M

No

12

7/15/2015

Series A

SiteOne Therapeutics

$1.28M

Yes

2

7/2/2015

Series A

Subscribe to see more

$99M

Subscribe to see more

10

9/23/2014

Seed

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/6/2017

1/6/2017

7/15/2015

7/2/2015

9/23/2014

Round

Series B

Series B

Series A

Series A

Seed

Company

SiteOne Inc.

SiteOne Therapeutics

SiteOne Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$15M

$15M

$1.28M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

12

2

10

10

Sears Capital Management Portfolio Exits

5 Portfolio Exits

Sears Capital Management has 5 portfolio exits. Their latest portfolio exit was Vital Therapies on April 17, 2014.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/17/2014

IPO

$99M

Public

2

3/24/2010

IPO

Subscribe to see more

$99M

Subscribe to see more

0

12/23/2009

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/19/2005

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/8/2000

IPO

Subscribe to see more

$99M

Subscribe to see more

0

Date

4/17/2014

3/24/2010

12/23/2009

4/19/2005

6/8/2000

Exit

IPO

IPO

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

0

10

10

0

Sears Capital Management Fund History

1 Fund History

Sears Capital Management has 1 fund, including Sears Trust.

Closing Date

Fund

Fund Type

Status

Amount

Sources

5/31/1994

Sears Trust

Early-Stage Venture Capital

Closed

$20M

1

Closing Date

5/31/1994

Fund

Sears Trust

Fund Type

Early-Stage Venture Capital

Status

Closed

Amount

$20M

Sources

1

Sears Capital Management Team

1 Team Member

Sears Capital Management has 1 team member, including current Chief Executive Officer, Lowell E. Sears.

Name

Work History

Title

Status

Lowell E. Sears

Chief Executive Officer

Current

Name

Lowell E. Sears

Work History

Title

Chief Executive Officer

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.